Live Breaking News & Updates on Hankang Capital

Stay updated with breaking news from Hankang capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Qunsheng Ji , China National Medical Products Administration , China National Medical Products , Sirius Therapeutic Chief Executive , Sirius Therapeutics , Creacion Ventures , Hankang Capital , Delos Capital ,

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Qunsheng Ji , Sirius Therapeutics Chief Executive , Sirius Therapeutics , Creacion Ventures , Hankang Capital , Delos Capital ,

China Digest: Pixocial, Sirius Therapeutics and LimX Dynamics in funding news

Pixocial, a wholly-owned subsidiary of Meitu, has raised $22 million in a funding round led by Eight Roads. ....

Hong Kong , Incubator Group , Orbimed Healthcare Fund Management , Eight Roads , Hankang Capital , Vitalbridge Capital , Limx Dynamics , Hong Kong Headquartered Futurex Capital , Creacion Ventures , Lenovo Capital , Future Capital , Kinzon Capital ,

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

/PRNewswire/ HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today. ....

Jing Lou , United States , Steven Dasong Wang , Zhenping Zhu , Research At Imclone Systems , Sunshine Guojian Pharmaceutical Shanghai Co Ltd , Sbio Group , Kadmon Holdings , Bio Therapeutics , Hankang Capital , Yonghua Investment , Sunshine Guojian Pharmaceutical , Chief Executive Officer , Chief Scientific Officer , Executive Vice President , Vice President , Global Head , Protein Sciences , Novartis Biologics , Sunshine Guojian , Quanhong Yuan , Hanbio Therapeutics ,

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

/PRNewswire/ HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today. ....

Jing Lou , United States , Steven Dasong Wang , Zhenping Zhu , Research At Imclone Systems , Sunshine Guojian Pharmaceutical Shanghai Co Ltd , Sbio Group , Kadmon Holdings , Bio Therapeutics , Hankang Capital , Yonghua Investment , Sunshine Guojian Pharmaceutical , Chief Executive Officer , Chief Scientific Officer , Executive Vice President , Vice President , Global Head , Protein Sciences , Novartis Biologics , Sunshine Guojian , Quanhong Yuan , Hanbio Therapeutics ,